Ideas in this flowchart

• Therapy effectiveness is driving innovation and clinical exploration.
• Radiopharmaceutical development in prostate cancer
• Pluvicto has successfully targeted PSMA-expressing prostate tumors.
• Radiopharmaceutical use in metastatic prostate cancer has increased four-fold since 2021.
• Radiopharmaceuticals are now the second most common treatment for these patients after chemotherapy.
• Global Oncology Trends 2025 reports the increase and treatment ranking.
• Radiopharmaceutical development in breast cancer
• Clinical trials are exploring investigational RLTs for breast cancer.
• The investigational RLTs are being combined with bispecific antibodies and immunotherapies to overcome tumor heterogeneity and enhance immune activation.
• Giugliano et al. (2025) report on these breast cancer clinical trials.